Overview

• The platform co-cultures patient-derived EAC organoids with tumor-associated fibroblasts in a microfluidic Organ Chip that reconstructs key features of the tumor microenvironment.
• Researchers obtain chemotherapy sensitivity and resistance readouts within 12 days, enabling rapid stratification of patients into responders and non-responders.
• In the pilot study, chip-predicted responses for all eight patients matched their actual neoadjuvant chemotherapy outcomes with perfect accuracy.
• By integrating stromal fibroblasts and extracellular matrix components, the system overcomes limitations of standard organoid models in replicating in vivo drug responses.
• With initial validation complete, the platform is poised for expanded clinical trials and will serve as a preclinical testbed for targeted therapies and biomarker discovery.